Opinion: I learned up close and personal about the necessity of improving diversity in clinical trials
As the biopharmaceutical industry places increased emphasis on improving the diversity of participants in clinical trials to create more equitable drugs, some are questioning this effort. As a biotech executive and a trial participant, I’ve seen firsthand why it’s needed.
A year ago, the industry trade association PhRMA convened more than 150 biopharma organizations for a workshop on clinical trial diversity. Since then, companies have listened to thousands of patients, health care providers, and health equity experts to understand the problem and identify solutions.
